Informatie:
Fout:
ID
34154
Beschrijving
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32; ODM derived from: https://clinicaltrials.gov/show/NCT01286233
Link
https://clinicaltrials.gov/show/NCT01286233
Trefwoorden
Versies (1)
- 14-01-19 14-01-19 -
Houder van rechten
see on clinicaltrials.gov
Geüploaded op
14 januari 2019
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY 4.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Eligibility Breast Cancer NCT01286233
Eligibility Breast Cancer NCT01286233
- StudyEvent: Eligibility
Similar models
Eligibility Breast Cancer NCT01286233
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
ID.1
Item
the patient must have consented to participate and must have signed and dated an appropriate irb-approved consent form that conforms to federal and institutional guidelines for the ma.32.f study before being enrolled.
boolean
ID.2
Item
the patient must be female.
boolean
ID.3
Item
the patient must reside in the united states or canada.
boolean
ID.4
Item
the patient must be english-speaking.
boolean
ID.5
Item
the patient must be eligible for randomization in the ma.32 treatment trial. (participation in the ma.32 qol study is permitted but not required.)
boolean
ID.6
Item
the patient must not have started taking ma.32 study therapy.
boolean
ID.7
Item
the patient must have completed primary breast radiation therapy at least two weeks prior to enrollment in ma.32.f.
boolean
ID.8
Item
ma.32 study therapy has been initiated.
boolean
ID.9
Item
currently receiving radiation therapy or additional radiation therapy is planned for initiation after starting ma.32 study therapy.
boolean